Simultaneous infection with Blastomyces dermatitidis and Cryptococcus neoformans

Medical Mycology

Volumn 36, Issue 1, 1998, Pages 47-50

  Mounts, Anthony ^a   Deepe Jr , George S ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blastomyces dermatitidis; Cryptococcus neoformans; Fungal pathogens

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CASE REPORT; COMORBIDITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGUS IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE;

AJELLOMYCES DERMATITIDIS; BLASTOMYCES; FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 33746388814     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/02681219880000081     Document Type: Article

References (15)

1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-48.
2. Pappas PG, Threlkeld MG, Bedsole GD, Cleveland KO, Gelfand MS, Dismukes WE. Blastomycosis in immunocompromised patients. Medicine 1993; 72: 311-25.
3. Recht LD, Davies SF, Eckman MR, Sarosi GA. Blastomycosis in immunosuppressed patients. Am Rev Respir Dis 1982; 125: 359-62.
4. Bradsher RW. Blastomycosis. Clin Infect Dis 1992; 14(Suppl. 1): S82-90.
5. Salfelder K, Mendelovici M, Schwarz J. Multiple deep fungus infections: personal observations and a critical review of the world literature. Curr Top Pathol 1973; 57: 123-77.
6. Tynes M, Mason KN, Jennings AE, Bennett JE. Variant forms of pulmonary cryptococcosis. Ann Intern Med 1968; 69: 1117-25.
7. Hammerman KJ, Powell KE, Christianson CS, et al. Pulmonary cryptococcosis: clinical forms and treatment. Am Rev Respir Dis 1973; 108: 1116-23.
8. Duperval R, Hermans PE, Brewer NS, Roberts GD. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 1977; 72: 13-19.
9. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis. Clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981; 94: 611-16.
10. Murphy JW, Wu-Hsieh BA, Singer-Vermes LM, et al. Cytokines in the host response to mycotic agents. J Med Vet Mycol 1994; 32(Suppl. 1): 203-10.
11. Collins HL, Bancroft GJ. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun 1991; 59: 3883-88.
12. Vecchiarelli A, Pietrella D, Dottorini M, et al. Encapsulation of Crvptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 1994; 98: 217-23.
13. Breen JF, Lee IC, Vogel FR, Friedman H. Cryptococcal capsular polysaccharide-induced modulation of murine immune responses. Infect Immun 1982; 36: 47-51.
14. McKinsey DS, Kauffman CA, Pappas PG, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Fluconazole therapy for histoplasmosis. Clin Infect Dis 1996; 23: 996-1001.
15. Pappas PG, Bradsher RW, Chapman SW, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20: 267-71.